Andina Capital Management LLC Trims Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Andina Capital Management LLC lessened its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 51.1% in the third quarter, Holdings Channel reports. The fund owned 3,370 shares of the medical equipment provider’s stock after selling 3,525 shares during the quarter. Andina Capital Management LLC’s holdings in Lantheus were worth $370,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of the company. abrdn plc purchased a new stake in Lantheus during the third quarter valued at $662,000. Smith Group Asset Management LLC increased its position in Lantheus by 24.2% during the third quarter. Smith Group Asset Management LLC now owns 6,023 shares of the medical equipment provider’s stock valued at $661,000 after acquiring an additional 1,172 shares during the last quarter. Nisa Investment Advisors LLC increased its position in Lantheus by 17.7% during the third quarter. Nisa Investment Advisors LLC now owns 7,819 shares of the medical equipment provider’s stock valued at $858,000 after acquiring an additional 1,176 shares during the last quarter. Klein Pavlis & Peasley Financial Inc. bought a new stake in Lantheus during the third quarter valued at about $237,000. Finally, State of Alaska Department of Revenue grew its holdings in Lantheus by 7.2% during the third quarter. State of Alaska Department of Revenue now owns 8,082 shares of the medical equipment provider’s stock valued at $886,000 after purchasing an additional 545 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

Lantheus stock traded up $1.28 during midday trading on Tuesday, reaching $111.38. 251,139 shares of the stock traded hands, compared to its average volume of 956,072. The stock’s fifty day moving average is $107.57 and its 200-day moving average is $93.51. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The stock has a market cap of $7.72 billion, a P/E ratio of 16.81 and a beta of 0.50. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The firm had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. During the same period in the previous year, the company posted $1.40 earnings per share. Lantheus’s quarterly revenue was up 22.5% on a year-over-year basis. As a group, equities research analysts anticipate that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 10,481 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the sale, the director now directly owns 454,923 shares in the company, valued at $43,445,146.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Lantheus news, Director Mary Anne Heino sold 10,481 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the sale, the director now directly owns 454,923 shares in the company, valued at $43,445,146.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the sale, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,981 shares of company stock valued at $2,689,156. Insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on LNTH shares. JMP Securities cut their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Redburn Atlantic started coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target for the company. Leerink Partners boosted their price target on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Truist Financial cut their price target on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Finally, B. Riley boosted their price target on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.